The NeuroAiD™ stroke treatment was historically developed in China as a traditional Chinese medicine to help stroke patients achieve better rehabilitation at late stage. After 5 years, it is now reaching about 200,000 patients every year in Asia, as well as patients in over 30 countries.
Moleac, a bio-pharmaceutical company, has identified NeuroAiD™ and its potential to meet the needs of stroke survivors and is bringing NeuroAiD™ to western medicine internationally and ensures it meets western medicine standards to attend to the needs of stroke sufferers, supporting them to achieve better neurological and functional recovery.
NeuroAiD™ is a natural medicine made of 14 components carefully selected for their efficacy and absence of side effects. They are extracted and mixed with a proprietary industrial process which ensures high quality standards. Since 2006, patients in more than 30 countries have used the NeuroAiD™ medication.
NeuroAiD™ is to be taken by stroke patients after the stroke for faster and better recovery regaining independence as well as from the loss of motor, cognitive and sensory neurological functions. NeuroAiD™ clinical impact on neurological functions has been documented and is being published.
Several studies have been conducted on the efficacy for patients several months after their stroke and show that patients taking NeuroAiD™ recover better independence.
NeuroAiD™ safety profile has been validated by several trials which have shown it does not significantly affect hematological, hemostatic, and biochemical parameters nor interacts with aspirin when started and maintained at the early stage of acute stroke. NeuroAiD™ has been available in China for nearly 5 years and no severe adverse reactions were reported. See medical data section. Side effects recorded by Moleac include rare case of minor headaches, and increased thirst.
NeuroAiD™ has been welcomed by the media and by clinicians worldwide. Our current international trial on 1,100 patients, conducted through the CHIMES society in Asia, to assess the benefits of NeuroAiD™ when given within the first 48 hours and ultimately systematize NeuroAiD™ use as early as possible in the stroke units, is the largest ever trial on a medicine for stroke recovery ever conducted. It is implemented in Asia and has recently been awarded a landmark research grant.
What is NeuroAiD™ composition?
The NeuroAiD™ stroke treatment capsule is a proprietary blend of ingredients from the Chinese Pharmacopoeia selected from consistent sources and extracted in a standardized proprietary manufacturing process with strict quality and Good Manufacturing Practices (GMP) compliance.
Each NeuroAiD™ capsule weighs 0.4 grams and contains extracts from the following main raw materials:
| Latin Name | Qty* (mg) |
|---|---|
| Radix astragali | 570 mg |
| Radix Salviae Miltiorrhizae | 114 mg |
| Radix Paeoniae Rubra | 114 mg |
| Rhizoma chuanxiong | 114 mg |
| Radix angelicae sinensis | 114 mg |
| * Each 0.4g of capsule contains extracts equivalent to raw herbs | |
Recommended dosage is four capsules, three times a day for four weeks as one treatment course (10 boxes). The first results are usually observed within the first month, and we recommend 3 courses of one-month treatment.
Singapore
